Evaluation of the drug interaction between magnesium oxide and levofloxaci
- Conditions
- Patients who decided prophylactic administration of levofloxacin is necessary
- Registration Number
- JPRN-UMIN000011518
- Lead Sponsor
- Department of Pharmacy, Gunma Prefectural Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 26
Not provided
1) Patients with a known allergy or hypersensitivity to any component of levofloxacin. 2) Patient who is unable to comply with dietary restriction*. *Patients taking prohibited medications and supplements high in metallic cations (e.g. sucralfate, iron pill, milk, yogurt, etc.) 3) Patients who have donated over 200 ml of blood within 2 weeks of therapy. 4) Female patients who are pregnant or breast feeding and women suspected of being pregnant. 5) Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of levofloxacin (e.g. ulcerative disease, malabsorption syndrome or small bowel resection). 6) Participation in a clinical trial within 12 weeks before registration. 7) Patients deemed ineligible by the attending physicians for various reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method area under the blood concentration-time curve (AUC)
- Secondary Outcome Measures
Name Time Method